CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 26 enrolled
Drug / intervention
Femara (Sequence 1) +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01084499
NCT01084499N/ACompleted
CompareCT.gov

Bioequivalence Study of YUHAN Letrozole 2.5 mg Tablets

Yuhan Corporation·interventional·Posted Mar 10, 2010·Updated Mar 29, 2019

In Brief

A clinical study evaluating Femara (Sequence 1), Peratra (Sequence 1), and 2 other interventions for Healthy. Completed, enrolled 26 participants.

Detailed Summary

Bioequivalence

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
Countries--
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 10, 2010
Enrollment StartJan 1, 2009
Primary CompletionApr 1, 2009
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 16.3 years ago

Interventions

Femara (Sequence 1)drug

Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.

Peratra (Sequence 1)drug

Participant who is assigned to the Sequence 1 first receive Femara, then a Peratra. Each treatment period is separated by a 5-week washout period.

Femara (Sequence 2)drug

Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.

Peratra (Sequence 2)drug

Participant who is assigned to the Sequence 2 first receive Peratra, then a Femara. Each treatment period is separated by a 5-week washout period.